With @abigailsuwala.bsky.social we are looking for a postdoc to drive our spatial transcriptomics analysis efforts of brain tumours.
If you enjoy multidisciplinary biomedical research, big data and coding, you are in the right place.
karriere.klinikum.uni-heidelberg.de/index.php?ac...
With @abigailsuwala.bsky.social we are looking for a postdoc to drive our spatial transcriptomics analysis efforts of brain tumours.
If you enjoy multidisciplinary biomedical research, big data and coding, you are in the right place.
karriere.klinikum.uni-heidelberg.de/index.php?ac...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Microglia across evolution: from conserved origins to functional divergence | Cellular
www.nature.com/articles/s41...
Microglia across evolution: from conserved origins to functional divergence | Cellular
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
www.uniklinik-freiburg.de/karriere/ste...
www.uniklinik-freiburg.de/karriere/ste...
🗓 November 11, 2025 | 🕓 16:30–17:30 CET
👥 Open to all EANO members | Free of charge
🔗 Learn more: www.eano.eu
🗓 November 11, 2025 | 🕓 16:30–17:30 CET
👥 Open to all EANO members | Free of charge
🔗 Learn more: www.eano.eu
www.jci.org/articles/vie...
www.jci.org/articles/vie...
https://www.researchsquare.com/article/rs-7746241/latest
https://www.researchsquare.com/article/rs-7746241/latest
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
academic.oup.com/neuro-oncolo...
@cellcellpress.bsky.social www.cell.com/cell/fulltex...
@cellcellpress.bsky.social www.cell.com/cell/fulltex...
We look forward to meeting you all in #Prague!
#NeuroOncology #btsm
We look forward to meeting you all in #Prague!
#NeuroOncology #btsm
https://www.biorxiv.org/content/10.1101/2025.10.12.681832v1
https://www.biorxiv.org/content/10.1101/2025.10.12.681832v1
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
@dkfz.bsky.social
The immunology of brain tumors
www.science.org/doi/10.1126/...
@dkfz.bsky.social
The immunology of brain tumors
www.science.org/doi/10.1126/...
🔗 www.biorxiv.org/content/10.1...
🔗 www.biorxiv.org/content/10.1...
nature.com/articles/d41...